transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2018-5-6-31-40transmed-446Research ArticleБИОФАРМАЦЕВТИЧЕСКИЕ И ВЕТЕРИНАРНЫЕ ТЕХНОЛОГИИBIOPHARMACEUTICAL AND VETERINARY TECHNOLOGIESИММУНОЛОГИЧЕСКИЕ ИЗМЕНЕНИЯ ПРИ ИНВАЗИИ HELICOBACTER PYLORI: ПЕРСПЕКТИВЫ СОЗДАНИЯ ВАКЦИНIMMUNOLOGICAL CHANGES IN THE INVASION OF HELICOBACTER PYLORI: PROSPECTS FOR CREATING VACCINESУспенскийЮ. П.UspenskiyYu. P.

д.м.н., профессор, заведующий кафедрой факультетской терапии имени Вальдмана, СПбГПМУ, профессор кафедры внутренних болезней стоматологического факультета ПСПбГМУ имени И. П. Павлова

ул. Льва Толстого, 6/8, Санкт-Петербург, Россия, 197022

MD, Doctor of Science, Professor, Head of faculty therapy department named after Valdman Pediatric Saint Petersburg State Medical University, Professor of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University

uspenskiy65@mail.ruГорбачеваИ. А.GorbachevaI. A.

д.м.н., профессор, заведующая кафедрой внутренних болезней стоматологического факультета

ул. Льва Толстого, 6/8, Санкт-Петербург, Россия, 197022

MD, Doctor of Science, Professor, Head of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University

baryshnikova_nv@mail.ruСуворовА. Н.SuvorovA. N.

чл.-корр. РАН, д.м.н., профессор, руководитель отдела молекулярной микробиологии

Associate of the Russian Academy of Science, MD, PhD, Professor, Head of Molecular microbiology department of the Institute of Experimental Medicine

alexander_suvorov1@hotmail.comГалагудзаМ. М.GalagudzaM. M.

чл.-корр. РАН, д.м.н., проф., директор Института экспериментальной медицины ФГБУ «НМИЦ им. В. А. Алмазова»

Associate of the Russian Academy of Science MD, PhD, Professor, Head of the Institute of Experimental Medicine, Almazov National Medical Research Centre

galagoudza@mail.ruhttps://orcid.org/0000-0001-7429-0336БарышниковаН. В.BaryshnikovaN. V.

к.м.н., доцент кафедры внутренних болезней стоматологического факультета ПСПбГМУ имени И. П. Павлова, научный сотрудник отдела молекулярной микробиологии ФГБНУ «ИЭМ»

ул. Льва Толстого, 6/8, Санкт-Петербург, Россия, 197022

MD, PhD, Associate Professor of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University, Science Employer of Molecular microbiology department of the Institute of Experimental Medicine

L’va Tolstogo str., 6/8, Saint Petersburg, Russia, 197022

baryshnikova_nv@mail.ruБогдановаС. А.BogdanovaS. A.

клинический ординатор, кафедра внутренних болезней стоматологического факультета ПСПбГМУ имени И. П. Павлова

ул. Льва Толстого, 6/8, Санкт-Петербург, Россия, 197022

Clinical Ordinator of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University

baryshnikova_nv@mail.ruФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова»РоссияPediatric Saint Petersburg State Medical University, Pavlov First Saint Petersburg State Medical UniversityRussian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова»Russian FederationPavlov First Saint Petersburg State Medical UniversityRussian FederationФГБНУ «Институт экспериментальной медицины»Russian FederationScience Research InstituteRussian FederationФГБУ «Национальный медицинский исследовательский центр имени В. А. Алмазова»Russian FederationAlmazov National Medical Research CentreRussian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» ФГБНУ «Институт экспериментальной медицины»РоссияPavlov First Saint Petersburg State Medical University, Science Research InstituteRussian Federation201809022019563140Copyright © Успенский Ю.П., Горбачева И.А., Суворов А.Н., Галагудза М.М., Барышникова Н.В., Богданова С.А., 20192019Успенский Ю.П., Горбачева И.А., Суворов А.Н., Галагудза М.М., Барышникова Н.В., Богданова С.А.Uspenskiy Y.P., Gorbacheva I.A., Suvorov A.N., Galagudza M.M., Baryshnikova N.V., Bogdanova S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/446

В статье описаны основные иммунологические нарушения, происходящие на фоне инвазии инфекции Helicobacter pylori (нарушения местного, клеточного и гуморального иммунитета, изменения уровня цитокинов). Представленные собственные данные об изменении уровня провоспалительных и противовоспалительных цитокинов в условиях персистенции cagA(+) и cagA(−) штаммов микроорганизма показывают, что уровень провоспалительного интерлейкина-1β и интерлейкина-8 выше, а уровень противовоспалительного интерлейкина-4 ниже в случае инвазии cagA(+) штаммами. Данные исследований по созданию антихеликобактерных вакцин как средств  иммунологической профилактики инфицирования Helicobacter pylori демонстрируют, что перспективным направлением в совершенствовании вакцин против H. pylori является применение эффективных мукозальных адъювантов и использование иммуностимулирующих пробиотиков во время введения вакцины или рекомбинантных полезных бактерий, экспрессирующих иммуногенные антигенны H. pylori. 

In this article we wrote about main immunologic disorders in Helicobacter pylori infected patients (changes of local, cell and humoral immunity). We have our own data about changes of interleukins 1β, 4 and 8 level in cagA(+) and cagA(−) Helicobacter pylori strains infected patients: we saw that level of proinflammatory interleukin-1β and unterleukin-8 are higher and level of anti-inflammatory interleukin-4 are lower in patients infected cagA(+) strains of Helicobacter pylori. We demonstrated results of different studies about efficacy of anti-Helicobacter pylori vaccines as immunologic prophylaxis of this microorganism invasion: usage of mucosal adjuvants and usage of immunostimulating probiotics during vaccination have promising results.

Helicobacter pyloriиммунитетинтерлейкиныаллергиявакциныHelicobacter pyloriimmunityinterleukinesallergyvaccinesReferencesМаянский А.Н., Маянский Д.Н. Очерки о нейтрофиле и макрофаге. Новосибирск: Наука, 1989. с. 344.Mayanskiy AN, Mayanskiy DN. Essays on the neutrophil and macrophage. Novosibirsk: izdatel’stvo “Nauka”, 1989. p. 344. In Russian.Новиков Д.К., Новикова В.И. Оценка иммунного статуса. М.: Витебский мединститут, 1996. с. 282.Novikov DK, Novikova VI. Immune status assessment. M.: Vitebskiy medinstitut, 1996. p. 282. In Russian.Makristathis A, Rokita E, Labigne A. et al. Highly significant role of Helicobacter pylori urease in phagocytosis and production of oxygen metabolites by human granulocytes. J Infect Dis. 1998; 177(3):803–806.Makristathis A, Rokita E, Labigne A. et al. Highly significant role of Helicobacter pylori urease in phagocytosis and production of oxygen metabolites by human granulocytes. J Infect Dis. 1998; 177(3):803–806.Пиманов С.И. Эзофагит, гастрит и язвенная болезнь: Рук. для врачей. Н. Новгород: Изд-во НГМА, 2000. c. 376.Pimanov SI. Esophagitis, gastritis and peptic ulcer: a guide for doctors. N. Novgorod: izdatel’stvo NGMA, 2000. p. 386. In Russian.Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut. 2008;57(5):561–567.Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut. 2008;57(5):561–567.Cardoso CR, Teixeira G, Provinciatto PR et al. Modulation of mucosal immunity in a murine model of food-induced intestinal inflammation. Clin Exp Allergy. 2008;38(2):338–349.Cardoso CR, Teixeira G, Provinciatto PR et al. Modulation of mucosal immunity in a murine model of food-induced intestinal inflammation. Clin Exp Allergy. 2008;38(2):338–349.Чернин В.В. Язвенная болезнь, хронический гастрит и эзофагит в аспекте дисбактериоза эзофагогастродуоденальной зоны. Экспериментальная и клиническая гастроэнтерология. 2008;3:68–69.Chernin VV. Peptic ulcer, chronic gastritis and esophagitis in terms of dysbiosis esophagogastroduodenal area. Еxperimental and clinical gastroenterology. 2006;3:68–69. In Russian.Дубцова Е.А. Некоторые иммунологические аспекты язвообразования. Экспериментальная и клиническая гастроэнтерология. 2002;4:9–14.Dubcova EA. Some immunological aspects of ulceration. Experimental and clinical gastroenterology J. 2002; 4: 9–14. In Russian.Успенский Ю.П., Суворов А.Н., Барышникова Н.В. Инфекция Helicobacter pylori в клинической практике. СПб: ИнформМед, 2011. с. 572.Uspenskiy YP, Suvorov AN, Baryshnikova NV. Helicobacter pylori infection in clinical practice. SPb.: InformMed, 2011. р. 572. In Russian.Sharma CM, Hoffmann S, Darfeuille F et al. The primary transcriptome of the major human pathogen Helicobacter pylori. Nature. 2010;464(7286):250–255.Sharma CM, Hoffmann S, Darfeuille F et al. The primary transcriptome of the major human pathogen Helicobacter pylori. Nature. 2010;464(7286):250–255.D’Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter. 2009:14(1): 21–28.D’Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter. 2009:14(1): 21–28.Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212: 256–271.Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212: 256–271.Aebischer T, Meyer TF, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter. Helicobacter. 2010;15(1):21–28.Aebischer T, Meyer TF, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter. Helicobacter. 2010;15(1):21–28.Kaparakis M, Philpott DJ, Ferrero RL. Mammalian NLR proteins; discriminating foe from friend. Immunol Cell Biol. 2007;85(6):495–502.Kaparakis M, Philpott DJ, Ferrero RL. Mammalian NLR proteins; discriminating foe from friend. Immunol Cell Biol. 2007;85(6):495–502.Amedei A, Cappon A, Codolo G et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 2006;116(4):1092– 1101.Amedei A, Cappon A, Codolo G et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 2006;116(4):1092– 1101.Magen E, Mishal J, Schlesinger M et al. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. Helicobacter. 2007;12(5):567–571.Magen E, Mishal J, Schlesinger M et al. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. Helicobacter. 2007;12(5):567–571.Бережная Н.М., Чехун В.Ф., Сепиашвили Р.И. Эозинофилы, базофилы и иммуноглобулин Е в противоопухолевой защите. Аллергология и иммунология. 2005;6(1):38–49.Berezhnaya NM, Chehun VF, Sepiashvili RI. Eosinophils, basophils and immunoglobulin E in antitumor protection. Allergology and immunology. 2005;6(1):38–49. In Russian.Maloy KJ. Induction and regulation of inflammatory bowel disease in immunodeficient mice by distinct CD4+ T-cell subsets. Methods Mol Biol. 2007;380:327–335.Maloy KJ. Induction and regulation of inflammatory bowel disease in immunodeficient mice by distinct CD4+ T-cell subsets. Methods Mol Biol. 2007;380:327–335.Лазебник Л.В., Чернуцкая С.П., Гервазиева В.Б. и др. Роль H. pylori в развитии аллергических заболеваний у больных с поражением желудка и двенадцатиперстной кишки. Терапевтический архив. 2008;80(12):63–66.Lazebnik LB, Chernuckaya SP, Gervazieva VB et al. The role of H. pylori in the development of allergic diseases in patients with lesions of the stomach and duodenum. Therapeutic archive. 2008;80(12):63–66. In Russian.Imamura S, Sugimoto M, Kanemasa K et al. Inverse association between Helicobacter pylori infection and allergic rhinitis in young Japanese. J Gastroenterol Hepatol. 2010;25 (7):1244–1249.Imamura S, Sugimoto M, Kanemasa K et al. Inverse association between Helicobacter pylori infection and allergic rhinitis in young Japanese. J Gastroenterol Hepatol. 2010;25 (7):1244–1249.Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med. 2007;167(8):821–827.Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med. 2007;167(8):821–827.Cоколова Н.Н., Кузин В.Б., Дугина В.В. и др. Исследование влияния дерината и ликопида на эрадикацию Helicobacter pylori у больных хронической язвенной болезнью желудка и двенадцатиперстной кишки. Медицинский альманах. 2011;2(15):188–190.Sokolova NN, Kuzin VB, Dugina VV et al. Study of the effect of Derinat and licopid on the eradication of Helicobacter pylori in patients with chronic ulcer disease of the stomach and duodenum. Medical almanac. 2011;2(15):188–190. In Russian.Ткаченко Е.И., Успенский Ю.П., Барышникова Н.В. Оптимизация лечения заболеваний, ассоциированных с Helicobacter pylori. Врач. 2012; 1: 36–38.Tkachenko EI, Uspenskiy YP, Baryshnikova NV. Optimization of treatment of diseases associated with Helicobacter pylori. Doctor. 2012;1:36–38. In Russian.Aebischer T, Schmitt A, Walduck AK et al. Helicobacter pylori vaccine development: facing the challenge. Int J Med Microbiol. 2005;295(5):343–353.Aebischer T, Schmitt A, Walduck AK et al. Helicobacter pylori vaccine development: facing the challenge. Int J Med Microbiol. 2005;295(5):343–353.Shi T, Liu WZ, Gao F et al. Intranasal CpGoligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter. 2005;10(1):71–79.Shi T, Liu WZ, Gao F et al. Intranasal CpGoligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter. 2005;10(1):71–79.Барышникова Н.В., Суворов А.Н., Ткаченко Е.И. и др. Роль генетических особенностей Helicobacter pylori в патогенезе заболеваний органов пищеварения: от теории к практике. Экспериментальная и клиническая гастроэнтерология. 2009;1:12–19.Baryshnikova NV, Suvorov AN, Tkachenko EI et al. The role of genetic features of Helicobacter pylori in the pathogenesis of diseases of the digestive system: from theory to practice. Experimental and clinical gastroenterology. 2009; 1: 12–19. In Russian.Del Giudice G, Covacci A, Telford JL et al. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol. 2001;19:523–563.Del Giudice G, Covacci A, Telford JL et al. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol. 2001;19:523–563.Vorobjova T, Watanabe T, Chiba T. Helicobacter pylori immunology and vaccines. Helicobacter. 2008;13(1):18–22.Vorobjova T, Watanabe T, Chiba T. Helicobacter pylori immunology and vaccines. Helicobacter. 2008;13(1):18–22.Ferrero RL, Thiberge JM, Kansau I et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA. 1995;92(14):6499–6503.Ferrero RL, Thiberge JM, Kansau I et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA. 1995;92(14):6499–6503.Cuenca R, Blanchard TG, Czinn SJ et al. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology. 1996;110(6):1770–1775.Cuenca R, Blanchard TG, Czinn SJ et al. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology. 1996;110(6):1770–1775.Stadtlander CT, Gangemi JD, Khanolkar SS et al. Immunogenicity and safety of recombinant Helicobacter pylori urease in a nonhuman primate. Dig Dis Sci. 1996;41(9):1853–1862.Stadtlander CT, Gangemi JD, Khanolkar SS et al. Immunogenicity and safety of recombinant Helicobacter pylori urease in a nonhuman primate. Dig Dis Sci. 1996;41(9):1853–1862.Michetti P, Corthésy-Theulaz I, Davin C et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology. 1994;107(4):1002–1011.Michetti P, Corthésy-Theulaz I, Davin C et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology. 1994;107(4):1002–1011.Smythies LE, Novak MJ, Waites KB et al. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine. 2005;23(7):901–909.Smythies LE, Novak MJ, Waites KB et al. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine. 2005;23(7):901–909.Todoroki I, Joh T, Watanabe K et al. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun. 2000;277(1):159–163.Todoroki I, Joh T, Watanabe K et al. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun. 2000;277(1):159–163.D’Elios MM, Andersen LP. Helicobacter pylori inflammation, immunity, and vaccines. 2007;12(1):15–19.D’Elios MM, Andersen LP. Helicobacter pylori inflammation, immunity, and vaccines. 2007;12(1):15–19.Nedrud JG, Bagheri N, Schön K et al. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS One. 2013;8(12):e83321.Nedrud JG, Bagheri N, Schön K et al. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS One. 2013;8(12):e83321.Chionh YT, Arulmuruganar A, Venditti E et al. Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant. Vaccine. 2014;32(20):2350–2358.Chionh YT, Arulmuruganar A, Venditti E et al. Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant. Vaccine. 2014;32(20):2350–2358.Sjökvist Ottsjö L, Flach CF, Clements J et al. A double mutant heat-labile toxin from Escherichia coli, LT (R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun. 2013;81(5):1532–1540.Sjökvist Ottsjö L, Flach CF, Clements J et al. A double mutant heat-labile toxin from Escherichia coli, LT (R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun. 2013;81(5):1532–1540.Zhang HX, Qiu YY, Zhao YH et al. Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant. Mol Cell Probes. 2014;28(1):25–30.Zhang HX, Qiu YY, Zhao YH et al. Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant. Mol Cell Probes. 2014;28(1):25–30.Anderl F, Gerhard M. Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol. 2014;20(34):11939–11949.Anderl F, Gerhard M. Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol. 2014;20(34):11939–11949.Aebischer T, Bumann D, Epple HJ et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21abased Salmonella vaccines. Gut. 2008;57(8):1065–1072.Aebischer T, Bumann D, Epple HJ et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21abased Salmonella vaccines. Gut. 2008;57(8):1065–1072.Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology. 2008;135:787–795.Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology. 2008;135:787–795.Zeng M, Mao XH, Li JX et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(10002):1457–1464.Zeng M, Mao XH, Li JX et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(10002):1457–1464.Успенский Ю.П., Барышникова Н.В. Функциональная диспепсия и хронический гастрит. Педиатр. 2018; 9(1) :77–83.Uspenskiy YP, Baryshnikova NV. Functional dyspepsia and chronic gastritis. Pediatrician. 2018;9(1):77– 83. In Russian.Гурова М.М., Успенский Ю.П. Интеллектуальные характеристики детей подросткового возраста с хроническими гастродуоденитами. Педиатр. 2017; 8(3):15–22.Gurova MM, Uspenskiy YP. Intellectual characteristics of adolescent children with chronic gastroduodenitis. Pediatrician. 2017;8(3):15–22. In Russian.

The authors declare that there are no conflicts of interest present.